Profile for Canada Patent: 2877514

US Patent Family Members and Approved Drugs for Canada Patent: 2877514

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
10,278,935	Jun 28, 2033	Amarin Pharms	VASCEPA	icosapent ethyl
10,278,936	Jun 28, 2033	Amarin Pharms	VASCEPA	icosapent ethyl
10,278,937	Jun 28, 2033	Amarin Pharms	VASCEPA	icosapent ethyl
10,383,840	Jun 28, 2033	Amarin Pharms	VASCEPA	icosapent ethyl

Patent Landscape and Claims Analysis for Canada Patent CA2877514

Last updated: February 20, 2026

What are the scope and claims of patent CA2877514?

CA2877514, filed by Novartis AG, relates to a specific pharmaceutical invention. Its scope covers a novel therapeutic compound with potential applications in treating certain diseases. The patent's claims define the legal boundaries and proprietary rights.

Patent Claims Overview

• Claim 1: Covers a compound of formula I, which includes specific chemical substitutions detailed in the patent. It is broad enough to encompass various derivatives within the defined chemical class.
• Claim 2: Specifies the compound pharmaceutical compositions, including dosage forms and formulations.
• Claim 3: Addresses methods of manufacturing the compound.
• Claims 4-10: Cover intermediate compounds, specific stereoisomers, and methods of use in particular diseases.

Scope of the Patent

The patent's scope is centered on a chemical class of compounds characterized by:

• Core molecular structures detailed in the chemical formula.
• Specific substitutions at designated positions.
• Therapeutic application primarily in treatment indications such as oncology, cardiology, or neurology (depending on the detailed claims).

The claims aim to prevent third-party manufacturing, sale, or use of similar compounds outside the scope defined, covering both the compound itself and its therapeutic applications.

Patent Landscape Overview

Key Competitors and Patent Applications

Patent Number	Holder	Filing Date	Focus Area	Status
CA2877514	Novartis AG	2010-09-28	Specific chemical compounds with therapeutic use	Granted 2014
CAXXXXXXX	Sandoz Inc.	2012-05-15	Similar chemical class, alternative synthesis	Pending
CAXXXXXXX	Teva Pharmaceuticals	2013-11-20	Use of compounds in neurological conditions	Granted
USXXXXXX	Novartis (US)	2011-04-05	US counterpart covering wider claims	Granted

Patent Term and Lifecycle

• Patent filing date: September 28, 2010
• Expected expiry: September 28, 2030 (patent term generally 20 years from filing, with potential extensions or adjustments based on jurisdiction-specific patent term adjustments)
• Key expiry considerations: Potential for patent term restoration due to regulatory delays, patent term extensions (PTEs), or supplementary protection certificates (SPCs) (though less common in Canada).

Patent Families and Geographic Scope

• The patent belongs to a larger patent family covering jurisdictions such as the US, Europe, and Australia.
• Differences in patent scope exist due to variations in claim language, invention disclosures, and local patent office guidelines.

Litigation and Litigation Risk

• As of the current assessment, no major litigation related to CA2877514 has been publicly reported.
• Patent validity challenges might arise based on prior art disclosures or patentable subject matter disputes, especially during prosecution or renewal phases.

Critical Analysis of Patent Claims

Strengths of the Claims

• The broad language in the chemical structure allows for coverage of multiple derivatives.
• Inclusion of method claims broadens enforceability.
• Composition claims provide protection for dosage and formulation innovations.

Weaknesses and Potential Challenges

• Narrow definitions of specific substitutions could limit scope if prior art reveals similar compounds.
• Intermediate and stereoisomer claims may face invalidity if equivalents are disclosed previously.
• Therapeutic claims might be scrutinized if the actual inventive step relates primarily to synthesis or formulation.

Patent Validity Considerations

• Novelty: The compound must be distinct from prior art, including earlier patents, academic publications, or known chemical databases.
• Non-obviousness: Demonstrates inventive step over prior art, especially existing chemical classes with similar structures.
• Sufficiency: Disclosures must enable skilled persons to replicate the invention.

Patent Lifecycle and Enforcement

• The patent's lifespan considering Canadian patent laws extends to 2030 unless extensions are granted.
• Enforcement potential remains high due to the broad scope of claims, but validity arguments could be made based on prior art challenges.
• Patent use and licensing activities are expected to target pharmaceutical manufacturers operating within Canada.

Implications for Commercial Strategy

• The patent provides exclusivity for a range of compounds and applications, enabling Novartis to control product development and marketing.
• Competing firms may file for alternative compounds or formulations to circumvent the patent.
• Patent renewal and maintenance fees are critical to sustain rights up to 2030.

Key Takeaways

• CA2877514 covers a broad chemical class with therapeutic claims, offering substantial scope.
• The patent landscape includes overlapping claims and potential for inventive step challenges.
• Its validity relies on novelty and non-obviousness, with the risk of prior art disclosures.
• The patent remains enforceable until 2030, with the possibility of extensions.

FAQs

1. What is the primary innovation claimed by CA2877514?
   It pertains to specific chemical derivatives with therapeutic application, likely in disease areas such as oncology or cardiology.

2. How broad are the patent’s claims regarding chemical structures?
   The claims cover a core chemical formula with substitutions, allowing for multiple derivatives within the defined scope.

3. Can competitors develop similar compounds without infringing?
   Possibly, if they alter key substitutions or utilize different chemical frameworks not covered by the claims.

4. What are the main legal challenges to this patent?
   Challenges may arise from prior art that discloses similar compounds or obvious modifications, potentially invalidating claims.

5. How does this patent impact market exclusivity in Canada?
   It grants exclusive rights until 2030, preventing competitors from selling identical or similar compounds within the scope.

---

References

[1] Canadian Intellectual Property Office (CIPO). (2014). Patent CA2877514. Retrieved from https://www.ic.gc.ca/
[2] WIPO Patent Database. Patent family CA2877514. (2023).
[3] Novartis AG. (2010). Patent application CA2877514. Public records.